Ask AI
ProCE Banner Activity

Navigating HER2-Negative MBC: An Oncology Nurse Roadmap to Maximize Efficacy and Enhance Tolerability With Antibody–Drug Conjugates

Slideset

Downloadable slides on the evolving ADC landscape in the management of patients with HER2-negative metastatic breast cancer, current role of TROP2-directed ADCs, efficacy and safety of TROP2-directed ADCs in advanced breast cancer, ways to optimize adverse event recognition, early intervention and quality-of-life preservation for patients receiving TROP2-directed ADCs, key ongoing trials of TROP2-directed ADCs in breast cancer, role of nurses in providing optimal care for patients receiving ADCs, and multidisciplinary team coordination and shared decision-making to improve patient care.

Released: September 02, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This activity is intended for oncology nurses and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss how structural, mechanistic, and unique characteristics, including the “bystander effect,” of antibody–drug conjugates contribute to differing toxicities and adverse event profiles

  • Identify and manage toxicities associated with TROP2-directed ADCs in breast cancer, applying strategies to mitigate these adverse events effectively

  • Apply evidence-based communication strategies to integrate patients’ treatment goals, preferences, and quality of life considerations into decisions related to ADC therapy selection and supportive care